PTC Therapeutics
PTCT
180 hedge funds and large institutions have $1.84B invested in PTC Therapeutics in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 81 increasing their positions, 58 reducing their positions, and 46 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 58
1.6% less ownership
Funds ownership: 109.3% → 107.7% (-1.6%)
12% less funds holding
Funds holding: 205 → 180 (-25)
21% less call options, than puts
Call options by funds: $8.48M | Put options by funds: $10.7M
44% less capital invested
Capital invested by funds: $3.3B → $1.84B (-$1.47B)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
50% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$108M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$98.5M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$33.5M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$18.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$66.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$46.7M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$43.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36.2M |
| 5 |
Bank of New York Mellon
New York
|
-$23.9M |
PTCT Hedge Fund Activity: Q3 2023 in Review
180 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2023, worth a combined $1.84B — down 44% from $3.3B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of PTCT and 23 opened new positions — a net loss of 23 holders — while 58 trimmed existing stakes and 81 added.
The largest buyer was Armistice Capital, adding an estimated $108M. The largest seller was Fidelity Investments, cutting an estimated $66.5M.
- 180 institutional investors held PTC Therapeutics (PTCT) as of Q3 2023, down from 205 in Q2 2023.
- Funds reported $1.84B of PTC Therapeutics stock for Q3 2023, down 44% quarter-over-quarter.
- 23 funds opened new PTC Therapeutics positions in Q3 2023 and 46 closed out, a net change of -23 holders.
- The largest PTC Therapeutics buyer in Q3 2023 was Armistice Capital, an estimated $108M added.
- The largest PTC Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $66.5M sold.
Based on aggregated 13F filings for Q3 2023.